newsfilter
← Latest News
Business Wire·

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved